Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
27.53
-0.86 (-3.03%)
At close: Jul 17, 2026, 4:00 PM EDT
28.34
+0.81 (2.94%)
After-hours: Jul 17, 2026, 7:34 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 522 employees as of March 31, 2026. The number of employees increased by 11 or 2.15% since the number was last reported on December 31, 2025.
Employees
522
Change
11
Growth
2.15%
Revenue / Employee
$314,197
Profits / Employee
-$126,398
Market Cap
2.74B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 522 | 11 | 2.15% |
| Dec 31, 2025 | 511 | 28 | 5.80% |
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 339 |
| uniQure | 221 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 154 |
| Kodiak Sciences | 130 |
| AtaiBeckley | 99 |
BEAM News
- 9 days ago - TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647 - TheFly
- 9 days ago - Resolution in favor of Prime has limited impact to Beam, says BofA - TheFly
- 9 days ago - Prime Medicine reports positive resolution to arbitration with Beam Therapeutics - TheFly
- 4 weeks ago - Beam Therapeutics announces U.S. FDA clearned IND application for BEAM-304 - TheFly
- 4 weeks ago - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration - GlobeNewsWire
- 4 weeks ago - The Healthcare M&A Wave - Forbes
- 6 weeks ago - Beam Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Beam Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts